Phase II success in HCC for c-MET inhibitor as monotherapy
This article was originally published in Scrip
Executive Summary
ArQule's tivantinib has met the primary endpoint in a Phase II trial in hepatocellular carcinoma (HCC). The product is the subject of a licensing agreement with Daiichi Sankyo.